Recent NUVB News
- Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting • Business Wire • 06/01/2024 12:10:00 PM
- Nuvation Bio to Present at the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 08:05:00 PM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 05/24/2024 09:22:30 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/24/2024 08:40:56 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:28:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:20:59 PM
- Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update • Business Wire • 05/14/2024 08:05:00 PM
- Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • Business Wire • 04/24/2024 02:01:00 PM
- Nuvation Bio Completes Acquisition of AnHeart Therapeutics • Business Wire • 04/10/2024 08:01:00 PM
- Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer • Business Wire • 03/28/2024 12:00:00 PM
- Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction • Business Wire • 03/25/2024 11:00:00 AM
- Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors • Business Wire • 03/14/2024 08:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/04/2024 10:30:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:22:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:40:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:27:28 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 10:06:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:48:41 PM
- Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • Business Wire • 02/29/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 09:22:44 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 09:21:29 PM
- Nuvation Bio Gets New Drug Application Clearance From FDA for Solid Tumor Treatment • Dow Jones News • 01/08/2024 09:58:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 09:17:00 PM
- Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors • Business Wire • 01/08/2024 09:10:00 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM